Figure 1.

Flow chart of clinical research design for newly diagnosed MDA5⁺DM patients. ALB, albumin; ANA, antinuclear antibody; ARS, minoacyl-tRNA synthetase; CRP, C reactive protein; CK, creatinine kinase; DLCO, carbon monoxide diffusing capacity; ELVAR, effective lung ventilation area ratio; ESR, erythrocyte sedimentation rate; Ferr, ferritin; FVC, forced vital capacity; ILD, interstitial lung disease; LDH, lactate dehydrogenase; MAA, myositis associated antibody; Mb, Myoglobin; MDA5, melanoma melanoma differentiation associated gene 5; MSA, myositis specific antibody; PCT, procalcitonin; P/F ratio, PaO2/FiO2 ratio; SRP, signal recognition particle; SAE, anti-small ubiquitin-like modifier antibody; TIF1-γ, transcription intermediary factor 1-gamma.